BioNTech eases 2024 revenue outlook despite hefty Covid vaccine third-quarter salesnews2024-11-04T18:46:43+00:00November 4th, 2024|Endpoints News|
FDA expands faster drug review pilot from supplemental to full applicationsnews2024-11-04T18:07:00+00:00November 4th, 2024|Endpoints News|
BioNTech says VEGF bispecific’s PD-L1 target, combo plans will be its edgenews2024-11-04T16:40:16+00:00November 4th, 2024|Endpoints News|
‘We play to win’: AstraZeneca details first results for oral GLP-1 and broader obesity ambitionsnews2024-11-04T15:55:13+00:00November 4th, 2024|Endpoints News|
MASH drug developers chart path forward as more patients use GLP-1snews2024-11-04T15:00:55+00:00November 4th, 2024|Endpoints News|
Viking’s oral weight loss drug shows promising Phase 1 datanews2024-11-04T02:18:03+00:00November 4th, 2024|Endpoints News|
Novo adds to Wegovy’s cardio strength with hospital admissions analysisnews2024-11-03T20:30:25+00:00November 3rd, 2024|Endpoints News|
BMS, J&J and AstraZeneca plea with appeals court to overturn drug price negotiationsnews2024-11-01T18:36:49+00:00November 1st, 2024|Endpoints News|
Heritage and Apotex to pay $49.1M in price-fixing settlementnews2024-11-01T16:36:10+00:00November 1st, 2024|Endpoints News|
Q&A with Obesity Society’s CEO as the field prepares for next-gen medsnews2024-11-01T11:00:10+00:00November 1st, 2024|Endpoints News|
